Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 16, 2019

View Archived Issues

LNC Therapeutics and INRA enter partnership to study anti-inflammatory properties of gut microbiome

Phase II trials of concizumab show clinical proof of concept for bleeding prevention in hemophilia

BET inhibitor JQ1(+) can be repurposed for lymphatic filariasis, new transcriptomics study suggests

Biogen discontinues development of gosuranemab for progressive supranuclear palsy

Phase II results for vasopressin V1B receptor antagonist TS-121 in MDD

Results reported from ongoing phase I study of FT-4202

ARX-788 well-tolerated in phase I study in Chinese patients with metastatic HER2+ breast cancer

Cirmtuzumab plus paclitaxel safe and well-tolerated in phase I study in breast cancer

Blood-brain barrier disruption could be Alzheimer's target

GDF1 unveiled as a therapeutic target for treating AML

Unexpected Ibrance MOA

Shanghai Zhimeng Biopharma describes potassium channel activators

Beijing Innocare Pharmaceutical Technology discovers IDO-1 inhibitors

Decoding EGFR's skin toxicity

New AXL/c-Met inhibitors disclosed by Shanghai Institute of Materia Medica

Shanghai Hengrui Pharmaceutical, Jiangsu Hengrui Medicine patent estrogen receptor antagonists

New PI3Kgamma/PI3Kdelta inhibitors synthesized at Incyte

Chitotriosidase-1 levels rise prior to onset of ALS symptoms

FDA approves Vascepa to reduce cardiovascular risk in adults with elevated triglyceride levels

LUSTER-1 and -2 results do not support further development of fevipiprant in asthma

MHRA clears initiation of phase I trial of brilacidin delayed-release tablets

Funding supports Synedgen's optimization of therapies to restore GI integrity in IBD

Ustekinumab biosimilar DMB-3115 begins phase I trial

Basilea to advance lisavanbulin development with biomarker-driven study

Wave Life Sciences discontinues development of suvodirsen for DMD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...